Chronic Granulomatous Disease (CGD) is a rare, inherited immunodeficiency caused by mutations in one or more components of the NADPH oxidase complex. This defect compromises the ability of phagocytes ...
Ensoma Inc. has obtained IND clearance from the FDA for its lead program EN-374 in X-linked chronic granulomatous disease (X-CGD). A phase I/II trial in both adult and pediatric patients with X-CGD is ...
Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...
-- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative -- - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback